Gan & Lee Pharmaceuticals. (SHA: 603087)
China
· Delayed Price · Currency is CNY 39.51
-0.59 (-1.47%)
Sep 6, 2024, 3:00 PM CST
Gan & Lee Pharmaceuticals. Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 504.82 | 340.07 | -439.52 | 1,453 | 1,231 | 1,167 | Upgrade
|
| Depreciation & Amortization | 235.28 | 219.04 | 200.34 | 184.88 | 159.6 | 115.83 | Upgrade
|
| Other Amortization | 4.67 | 7.99 | 1.77 | 1.74 | 1.8 | 1.6 | Upgrade
|
| Loss (Gain) From Sale of Assets | 16.84 | 17.58 | 80.17 | 0 | -0.33 | 1.68 | Upgrade
|
| Asset Writedown & Restructuring Costs | -140.77 | 13.38 | 46.58 | 1.69 | 6.85 | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -73.8 | -63.33 | -87.57 | -85.63 | -20.47 | -68.56 | Upgrade
|
| Provision & Write-off of Bad Debts | 21.44 | 15.96 | 27.25 | 19.39 | -4.94 | 1 | Upgrade
|
| Other Operating Activities | -37.5 | -43.57 | -50.7 | -141.11 | 2.9 | 4.68 | Upgrade
|
| Change in Accounts Receivable | 579.21 | 480.76 | 2,224 | -155.18 | -8.71 | -87.66 | Upgrade
|
| Change in Inventory | -221.17 | -239.14 | -35.44 | -158.47 | -25.3 | -98.6 | Upgrade
|
| Change in Accounts Payable | -792.58 | -665.1 | -1,546 | -30.39 | -91.71 | 100.22 | Upgrade
|
| Change in Other Net Operating Assets | 155.63 | 50.11 | 19.59 | - | - | - | Upgrade
|
| Operating Cash Flow | 233.85 | 109.45 | 296.68 | 1,078 | 1,241 | 1,158 | Upgrade
|
| Operating Cash Flow Growth | - | -63.11% | -72.48% | -13.14% | 7.23% | 176.91% | Upgrade
|
| Capital Expenditures | -543.17 | -553.06 | -983.44 | -692.08 | -582.14 | -406.63 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.17 | 0.36 | 0.06 | 1.02 | 0.86 | 0.01 | Upgrade
|
| Divestitures | - | - | - | - | - | 0.35 | Upgrade
|
| Investment in Securities | -1,022 | -744.48 | 328.42 | 56.66 | -2,663 | -851.3 | Upgrade
|
| Other Investing Activities | 377.72 | 319.78 | 212.52 | 136.27 | 21.7 | 82.31 | Upgrade
|
| Investing Cash Flow | -1,188 | -977.4 | -442.45 | -498.13 | -3,223 | -1,175 | Upgrade
|
| Issuance of Common Stock | 899.05 | 759.73 | 71.36 | - | 2,441 | - | Upgrade
|
| Common Dividends Paid | -101.41 | - | -168.46 | -224.62 | -200.55 | - | Upgrade
|
| Other Financing Activities | -4.18 | -5.03 | -3.77 | -4.32 | - | - | Upgrade
|
| Financing Cash Flow | 793.46 | 754.7 | -100.87 | -228.93 | 2,241 | - | Upgrade
|
| Foreign Exchange Rate Adjustments | -2.41 | 2.36 | 4.19 | -2.68 | -0.88 | 4.5 | Upgrade
|
| Net Cash Flow | -162.72 | -110.89 | -242.44 | 348.43 | 258.12 | -13.15 | Upgrade
|
| Free Cash Flow | -309.32 | -443.61 | -686.76 | 386.09 | 659.2 | 750.97 | Upgrade
|
| Free Cash Flow Growth | - | - | - | -41.43% | -12.22% | - | Upgrade
|
| Free Cash Flow Margin | -11.49% | -17.01% | -40.11% | 10.69% | 19.61% | 25.94% | Upgrade
|
| Free Cash Flow Per Share | -0.53 | -0.78 | -1.22 | 0.69 | 1.24 | 1.49 | Upgrade
|
| Cash Income Tax Paid | 26.91 | -5 | 116.25 | 323.56 | 438.86 | 261.38 | Upgrade
|
| Levered Free Cash Flow | -506.04 | -585.87 | -149.69 | 171.67 | 379.8 | 544.29 | Upgrade
|
| Unlevered Free Cash Flow | -505.87 | -585.52 | -149.21 | 172.28 | 379.8 | 544.29 | Upgrade
|
| Change in Net Working Capital | 359.68 | 422.13 | -1,054 | 191.15 | 83.72 | -2.79 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.